Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.43 |
| ▸ | PYGL | P06737 | 2/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.42 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926900 | 0.94 | ITGB1 (0.47) | ITGB1ITGA4ITGB7PYGLITGB2 | |
| SCHEMBL5926295 | 0.92 | ITGA4 (0.44) | GPR34ITGB1ITGA4ITGB7PYGL | |
| SCHEMBL8339646 | 0.90 | ITGB1 (0.44) | ITGB1ITGA4ITGB7PYGLITGB2 | |
| SCHEMBL5926158 | 0.90 | GPR34 (0.53) | GPR34ITGB1ITGA4ITGB7PTPN1 | |
| SCHEMBL8300159 | 0.88 | KIFC1 (0.47) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL3995086 | 0.88 | KIFC1 (0.47) | ITGB1ITGA4ITGB7ITGB2ICAM1 | |
| SCHEMBL6101133 | 0.88 | ITGB1 (0.44) | ITGB1ITGA4ITGB7PYGLITGB2 | |
| SCHEMBL5926694 | 0.87 | ITGB1 (0.47) | ITGB1ITGA4ITGB7PYGLITGB2 | |
| SCHEMBL5926907 | 0.86 | ITGB1 (0.45) | ITGB1ITGA4ITGB7PYGLITGB2 | |
| SCHEMBL3978076 | 0.85 | EGLN2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | GPR34 955/4885ITGB1 1520/4885ITGA4 1777/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | GPR34 4272/4885ITGB1 240/4885ITGA4 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.